News
Public · Published
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck said the European Medicines Agency's CHMP recommended approval of WELIREG, taken with lenvatinib, for adults with advanced kidney cancer of a specified type after anti-PD-1 or anti-PD-L1 treatment. The European Commission will review the recommendation, with a final decision expected within two months.
Published:
Updated:
What happened
Merck said the European Medicines Agency’s CHMP recommended approval of WELIREG, taken with lenvatinib, for adults with advanced kidney cancer of a specified type after anti-PD-1 or anti-PD-L1 treatment. The European Commission will review the recommendation, with a final decision expected within two months.
Confirmed
Global impact / market context
If the European Commission approves the combination, Merck could gain another treatment option for eligible kidney cancer patients in Europe, potentially supporting future medicine sales. Lenvatinib was discovered by Eisai, so the article also identifies a second company connected to the regimen, but gives no financial terms.
Analyst inference
The CHMP opinion is a recommendation, not marketing authorization: the European Commission still must decide whether the treatment can be sold in the EU and named neighboring countries. That remaining regulatory step means anticipated commercial access is not yet confirmed by this announcement.
Analyst inference
What to watch
- Watch for the European Commission’s final decision, expected within two months, which will determine whether the combination receives marketing authorization in the EU, Iceland, Liechtenstein and Norway. Confirmed
- If authorization is granted, assess whether Merck communicates a launch timetable and patient access plans; those details would clarify how quickly the recommendation could translate into sales. Analyst inference
- Look for further information on the combination’s commercial arrangement with Eisai, since the article names Eisai as lenvatinib’s discoverer but provides no financial terms. Analyst inference
Evidence
- Original source link unavailable